Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Oculis Holding AGNASDAQ: OCS

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q1 FY2026 other income / expenses was -CHF 7.17M, compared with -CHF 13.23M a year earlier. Trailing-twelve-month other income / expenses was -CHF 10.98M.

Context

  • Other income / expenses grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -CHF 7.17M or moves back toward the trailing-twelve-month quarterly average of -CHF 2.74M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 7.17M-172.4% QoQ
Last fiscal yearDec 2025
-CHF 15.54M-22.0% YoY
LTMMar 2026
-CHF 10.98M+56.5% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.8%——
1 year-22.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

CHF · from the income statement

Latest · FY2025
(15.54M) CHF
Year-over-year change
-22.0%

Other Income / Expenses vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +56.5% is the highest of 6, against a peer median of -28.8%.
  • Other income / expenses amounts to 2178.2% of revenue for OCS, versus a peer median of 77.2%.
OCS Competitors
Other Income / Expenses for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$10.45M USD-28.8%—137.3%
OCULOcular Therapeutix, Inc.LTM Mar 2026$8.94M USD-21.4%-18.8%17.2%
OKYOOKYO Pharma LimitedFY2025-$781.2K USD+29.5%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.94M USD-102.0%—581.4%
OCSOculis Holding AGLTM Mar 2026-CHF 10.98M CHF+56.5%—2178.2%
HROWHarrow Health, Inc.LTM Mar 2026-$39.28M USD-50.8%—14.6%
Peer median (excluding OCS) —-28.8%-18.8%77.2%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000686K0
Cost of Revenue00052.08M0
Gross Profit000(51.4M)0
Gross Margin———-7492.3%—
Research & Development9.57M22.22M29.25M52.08M54.52M
Selling, General & Admin4.1M6.74M14.72M21.81M24.63M
Operating Expenses13.23M32.38M80.71M21.81M79.15M
Depreciation & Amortization235K299K287K406K521.45K
EBITDA(13.17M)(31.9M)(87.09M)(85.53M)(93.37M)
EBITDA Margin———-12468.1%—
Operating Income(13.23M)(32.38M)(80.71M)(73.2M)(79.15M)
Operating Margin———-10671.1%—
Interest Income21K126K1.59M2.17M1.69M
Interest Expense5.12M6.44M1.46M639K795.55K
Other Income / Expenses(5.29M)(6.27M)(7.98M)(12.73M)(15.54M)
Income Before Tax(18.52M)(38.64M)(88.7M)(85.94M)(94.69M)
Pre-Tax Margin———-12527.3%—
Income Tax Expense27K55K107K(160K)177.64K
Net Income(18.55M)(38.7M)(88.8M)(85.78M)(94.51M)
Net Margin———-12503.9%—
EPS (Basic)(0.57)(1.18)(2.97)(2.12)(1.81)
EPS (Diluted)(0.57)(1.18)(2.97)(2.12)(1.81)
Weighted Avg Shares32.73M32.73M29.9M40.41M52.36M
Weighted Avg Shares (Diluted)32.73M32.73M29.9M40.41M52.36M

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.